GENTAUR Europe BVBA
Genprice Inc, Logistics
Serbia, 
Macedonia, 
Montenegro, 
Croatia: 
GENTAUR Romania
GENTAUR Greece 
PRODUCT DESCRIPTION:
Influenza viruses are enveloped viruses with a diameter of 80-120 nm, and contain a singlestranded, segmented, negative-sense RNA within a nucleocapsid. Influenza virus is propagated in the MDCK cell line. The virus is purified using sucrose density gradient
ultracentrifugation, disrupted in the presence of 0.5% Triton X-100 non-ionic detergent/0.6 M KCl, and heat inactivated. Influenza lysate is sold in vials containing 1.0 mg of protein, and is shipped on dry ice. Protein concentrations generally range from 0.5 to 3.0
mg/ml. Custom orders are available, including specific buffer formulations and package sizes.
INTENDED USE:
This product is intended for research, product development, quality assurance testing, or further manufacturing use. Viral lysates can be utilized as an antigen, as a source for the purification of viral proteins, or for the detection of viral antibodies.
Applications include:
- Immunodetection of antibodies to Influenza virus using solid-phase enzyme immunoassays (EIA)
- Western blot
- Dot blot
- Other protein-based assays
TIOLOGIC STATUS/BIOHAZARD TESTING:
Influenza virus is a Biosafety Level 2 organism. Viral inactivation is verified for every lot of lysate by the absence of viral growth in validated tissue culture based infectivity assays.
PRECAUTIONS:
USE UNIVERSAL PRECAUTIONS when handling this product! Influenza Lysate has been treated by a method validated to be effective for virus inactivation. However, no method can be guaranteed 100% effective. This material should be handled as if capable of transmitting infectious agents.
RECOMMENDED STORAGE:
The viral lysate is stable for at least one year when stored at -65ºC or below. To avoid repeat freeze-thaws, which could negatively impact product performance, viral lysateshould be stored in aliquots upon receipt.
DO NOT USE IN HUMANS!
These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act, or for any other product intended for administration to humans.
